MX379253B - Formulaciones de oximetazolina estabilizadas y sus usos. - Google Patents

Formulaciones de oximetazolina estabilizadas y sus usos.

Info

Publication number
MX379253B
MX379253B MX2016016400A MX2016016400A MX379253B MX 379253 B MX379253 B MX 379253B MX 2016016400 A MX2016016400 A MX 2016016400A MX 2016016400 A MX2016016400 A MX 2016016400A MX 379253 B MX379253 B MX 379253B
Authority
MX
Mexico
Prior art keywords
oxymetazoline
stabilized
patient
present
provides
Prior art date
Application number
MX2016016400A
Other languages
English (en)
Other versions
MX2016016400A (es
Inventor
Amy Kuang
Gurpreet Ahluwalia
Kevin Warner
Pramod Sarpotdar
Steven Zhang
Original Assignee
Epi Health Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53546693&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX379253(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Epi Health Llc filed Critical Epi Health Llc
Publication of MX2016016400A publication Critical patent/MX2016016400A/es
Publication of MX379253B publication Critical patent/MX379253B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención provee formulaciones en crema estabilizadas de oximetazolina y usos de estas. La presente invención también provee un método para tratar el eritema facial asociado a la rosácea que comprende la administración tópica una o más veces al día de una composición farmacéutica que comprende 0,5%, 1,0% o 1,5% de oximetazolina o una sal farmacéuticamente aceptable de esta como único ingrediente activo en el sitio del eritema en el rostro de un paciente que necesita dicho tratamiento.
MX2016016400A 2014-06-11 2015-06-11 Formulaciones de oximetazolina estabilizadas y sus usos. MX379253B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462010838P 2014-06-11 2014-06-11
US201462069624P 2014-10-28 2014-10-28
PCT/US2015/035420 WO2015191917A1 (en) 2014-06-11 2015-06-11 Stabilized oxymetazoline formulations and their uses

Publications (2)

Publication Number Publication Date
MX2016016400A MX2016016400A (es) 2017-06-12
MX379253B true MX379253B (es) 2025-03-11

Family

ID=53546693

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016016400A MX379253B (es) 2014-06-11 2015-06-11 Formulaciones de oximetazolina estabilizadas y sus usos.

Country Status (7)

Country Link
US (6) US9801857B2 (es)
EP (1) EP3154517B8 (es)
AU (1) AU2015274532B2 (es)
CA (1) CA2951725C (es)
ES (1) ES2796871T3 (es)
MX (1) MX379253B (es)
WO (1) WO2015191917A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120225918A1 (en) 2011-03-03 2012-09-06 Voom, Llc Compositions and Methods for Non-Surgical Treatment of Ptosis
CA2951725C (en) * 2014-06-11 2022-06-07 Allergan, Inc. Stabilized oxymetazoline formulations and their uses
CN108883308A (zh) 2016-01-26 2018-11-23 利维申制药有限公司 α-肾上腺素能药剂的组合物和用途
US11216742B2 (en) 2019-03-04 2022-01-04 Iocurrents, Inc. Data compression and communication using machine learning
JP7534795B2 (ja) 2019-05-01 2024-08-15 クレキシオ バイオサイエンシーズ エルティーディー． そう痒症を治療する方法
US10814001B1 (en) 2019-05-06 2020-10-27 Rvl Pharmaceuticals, Inc. Oxymetazoline compositions

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3147275A (en) 1964-09-01 Nh-cha
ATE226363T1 (de) 1999-05-19 2002-11-15 Fraunhofer Ges Forschung Vorrichtung und verfahren zum erwärmen von bauteilen aus mikrowellenabsorbierendem kunststoff
US6433024B1 (en) 2000-05-08 2002-08-13 Karl F. Popp Topical anti-acne composition
US6824786B2 (en) 2001-11-27 2004-11-30 Ruey J. Yu Compositions comprising phenyl-glycine derivatives
US6573301B1 (en) 2002-04-23 2003-06-03 Bradley Pharmaceuticals, Inc. Carbamide peroxide compositions for the treatment of dermatological disorders and methods for their use
US7439241B2 (en) * 2003-05-27 2008-10-21 Galderma Laboratories, Inc. Compounds, formulations, and methods for treating or preventing rosacea
US8410102B2 (en) * 2003-05-27 2013-04-02 Galderma Laboratories Inc. Methods and compositions for treating or preventing erythema
US7812049B2 (en) * 2004-01-22 2010-10-12 Vicept Therapeutics, Inc. Method and therapeutic/cosmetic topical compositions for the treatment of rosacea and skin erythema using α1-adrenoceptor agonists
WO2006098625A1 (en) 2005-03-15 2006-09-21 Campina Nederland Holding B.V. Dermatologic use of milk proteins
JP5129130B2 (ja) 2005-06-29 2013-01-23 ディーエスエム アイピー アセッツ ビー．ブイ． イソフラボンのナノ粒子を含む局所組成物
US20090061020A1 (en) 2007-08-31 2009-03-05 Theobald Klaus P Brimonidine Compositions for Treating Erythema
EP2818184B1 (en) 2007-11-16 2018-10-31 Allergan, Inc. Compositions and methods for treating Purpura
WO2012075319A2 (en) 2010-12-03 2012-06-07 Allergan, Inc. Pharmaceutical cream compositions and methods of use
ES2742273T3 (es) * 2011-02-15 2020-02-13 Aclaris Therapeutics Inc Composiciones de crema farmacéuticas de oximetazolina para tratar los síntomas de la rosácea
CA2841632A1 (en) * 2011-07-14 2013-01-17 Allergan, Inc. Gel compositions of oxymetazoline and methods of use
MX2014004383A (es) * 2011-10-19 2014-11-12 Galderma Sa Metodo para reducir el enrojecimiento facial asociado con el uso sistemico de inhibidores de fosfodiesterasa tipo 5.
CA2951725C (en) * 2014-06-11 2022-06-07 Allergan, Inc. Stabilized oxymetazoline formulations and their uses

Also Published As

Publication number Publication date
US20230346749A1 (en) 2023-11-02
ES2796871T3 (es) 2020-11-30
US10335391B2 (en) 2019-07-02
US11517560B2 (en) 2022-12-06
EP3154517A1 (en) 2017-04-19
NZ727233A (en) 2023-10-27
MX2016016400A (es) 2017-06-12
US20170151217A1 (en) 2017-06-01
US20180263962A1 (en) 2018-09-20
EP3154517B8 (en) 2020-06-03
US9801857B2 (en) 2017-10-31
US9974773B2 (en) 2018-05-22
US20190365713A1 (en) 2019-12-05
WO2015191917A1 (en) 2015-12-17
CA2951725C (en) 2022-06-07
US20210169855A1 (en) 2021-06-10
US20150359781A1 (en) 2015-12-17
EP3154517B1 (en) 2020-04-22
AU2015274532A1 (en) 2017-01-12
CA2951725A1 (en) 2015-12-17
US10751325B2 (en) 2020-08-25
AU2015274532B2 (en) 2020-06-11
US12350255B2 (en) 2025-07-08

Similar Documents

Publication Publication Date Title
JOP20200001A1 (ar) كاربوكسأميدات بوصفها معدلات لقنوات الصوديوم
CL2017002939A1 (es) Composiciones farmacéuticas tópicas
MX2021004639A (es) Combinaciones de inhibidores de desmetilasa-1 especifica de lisina (lsd1) para uso en el tratamiento de tumores solidos.
SA518391624B1 (ar) Ror- منظمات جاما
MX390627B (es) Uso de pridopidina para el tratamiento de la disminucion funcional.
MX2022009155A (es) Nuevos profarmacos polimericos de la hormona del crecimiento humana (hgh).
MX377576B (es) Formulaciones de pridopidina de liberación modificada.
CY1123366T1 (el) Παραγωγα 8-αμινο-2-οξο-1,3-διαζα-σπειρο-[4.5]-δeκανιου
MX379253B (es) Formulaciones de oximetazolina estabilizadas y sus usos.
NZ729252A (en) Methyl-and trifluoromethyl-substituted pyrrolopyridine modulators of rorc2 and methods of use thereof
MX2018000262A (es) Usos terapeuticos de formulaciones de berberina.
PH12016501519B1 (en) Solid pharmaceutical compositions comprising biopterin derivatives and uses of such compositions
BR112018015367A2 (pt) carreadores oromucosais de nanofibra para tratamento terapêutico
PH12018500910A1 (en) Novel method of use and compositions
PH12016502233A1 (en) (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine
PH12016502236A1 (en) (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine
MX381932B (es) Composicion intranasal que comprende betahistina.
EA202090416A1 (ru) Способы лечения симптомов гастропареза с использованием велусетрага
MX2018015240A (es) Composiciones que comprenden timolol y su uso en el tratamiento de rosacea mediante administracion topica.
TH167851A (th) (s)-เพอร์ลินโดล และเกลือที่ยอมรับได้ทางเภสัชกรรมของมันสำหรับ การใช้ในยารักษาโรค
HK1251178A1 (zh) 用於预防由放射疗法引起的皮肤损伤的可乐定和/或可乐定衍生物
WO2016115442A3 (en) Therapeutic protein formulations
EA201990553A1 (ru) Применение придопидина для лечения ухудшения функциональной способности
UA106472U (uk) Засіб для лікування дерматологічних захворювань
TH167850A (th) (r)-เพอร์ลินโดล และเกลือที่ยอมรับได้ทางเภสัชกรรมของมันสำหรับการใช้ ในยารักษาโรค